Constitutively active HER2/neu activates nuclear factor kappa-B (NF-jB) in cells and induces their resistance to apoptotic stimuli such as tumor necrosis factor-a (TNF-a). Here, we show that integrin-linked kinase (ILK), the crucial signal transducer in the integrin pathway, is involved in HER2/neu-mediated activation of NF-jB. Expression of HER2/neu increases ILK activity. Blocking ILK activity with a kinase-deficient mutant ILK (ILK-KD) inhibits NF-jB activation and sensitizes HER2/neutransformed cells to TNF-a-induced apoptosis. Stable expression of ILK-KD in HER2/neu-transformed cells suppressed Akt phosphorylation and the expression of IjB kinase a and b (IKKa and b) at both the protein and mRNA levels, preventing IjB-a degradation and NF-jB activation. Furthermore, HER2/neu stimulated the transcriptional activity of the putative IKKb promoter through ILK and Akt. Our results demonstrate that upregulation of IKKa and IKKb by the ILK/Akt pathway is required for the HER2/neu-mediated NF-jB antiapoptotic pathway.
Upon environmental stress, the fate of a cell depends on the balance between apoptotic and survival signals. Activation of receptor tyrosine kinases (RTKs) and the integrin family of adhesion receptors contributes to cell survival (Morino et al., 1995; Zhu and Assoian, 1995; Downward, 1998; Datta et al., 1999) . A synergism between these two types of receptors in the survival signaling has also been shown (Sundberg and Rubin, 1996; Renshaw et al., 1997; Gambaletta et al., 2000) . The b1 integrin cytoplasmic domain-binding protein, integrin-linked kinase (ILK), is crucial for the integrinmediated cell survival pathway. ILK overexpression blocks anoikis (Hannigan et al., 1996; Radeva et al., 1997) . It inhibits apoptosis by activating Akt, an essential downstream target of many RTKs (CruetHennequart et al., 2003; Gary et al., 2003) . Thus, ILK may play an important role in the crosstalk between RTK and integrin in the cell survival pathway.
The transcription factor nuclear factor kappa-B (NFkB) is a major inducer of stress-responding genes in the survival pathway. NF-kB is activated by diverse stimuli, such as tumor necrosis factor-a (TNF-a), chemotherapeutic agents, g-radiation, and growth factors, etc. RTKs like EGFR and HER2/neu (Karin et al., 2002) can also promote cell survival through NF-kB activation. Upon stimulation, NF-kB upstream molecules, IkB kinase (IKK)a, b, and g, are phosphorylated by NIK (Malinin et al., 1997; Ling et al., 1998) , MEKK1 (Lee et al., 1998; Nakano et al., 1998) , or Akt (Ozes et al., 1999; Romashkova and Makarov, 1999; Zhou et al., 2000) , and form a triad complex. This IKK complex then phosphorylates IkB, the NF-kB-sequestering molecule, resulting in its degradation. Subsequently, NF-kB is released and translocates to the nucleus to activate transcription (Palombella et al., 1994; Thanos and Maniatis, 1995) .
HER2/neu is overexpressed in many types of tumors and is related to advanced malignancy. A point mutation in the transmembrane region of HER2/neu causes its constitutive activation. This constitutively active HER2/neu activates multiple downstream pathways (e.g. AP-1, NF-kB, E2F-1, etc.), causing malignant transformation (Galang et al., 1996; Hung and Lau, 1999; Lee et al., 2000) , and inducing cellular resistance to therapeutic agents Tan et al., 2002b) . We have previously reported that HER2/neu blocked TNF-a-induced apoptosis through the activation of the PI-3K/Akt/NF-kB pathway (Zhou et al., 2000) . In this study, we investigated the role that ILK plays in the HER2/neu-induced cell survival pathway.
To determine the effect HER2/neu has on ILK, we examined ILK kinase activity and protein expression in NIH3T3, and the HER2/neu-transformed NIH3T3 (3T3-HER2) cells using an immunocomplex kinase assay and Western blot, respectively. ILK kinase activity, as shown by the myelin basic protein phosphorylation (p-MBP) levels, was significantly upregulated in 3T3-HER2 cells (Figure 1a , lane 3), while there was no significant difference in the ILK protein levels in the two cell lines (Figure 1b) . This indicated that HER2/ neu expression enhances ILK kinase activity without increasing its expression. Since it has been shown that PI-3K activates ILK (Delcommenne et al., 1998) , and PI-3K is downstream of HER2/neu, we therefore asked whether HER2/neu-induced ILK activity required PI-3K. 3T3-HER2 cells were treated with the RTK inhibitor emodin and PI-3K-specific inhibitor wortmannin, and then ILK activity was examined. Both inhibitors suppressed ILK kinase activity (Figure 1c , lanes 2 and 3) in 3T3-HER2 cells. However, only emodin inhibited tyrosine phosphorylation (PY20) of HER2/neu. This indicates that the RTK activity of HER2/neu is required to activate PI-3K and ILK, and confirms that ILK is downstream of PI-3K. As a control, we also determined the effects of the inhibitors on Akt, the molecule immediately downstream of PI-3K in the cell survival pathway. As expected, Akt phosphorylation (p-Akt) was also blocked by emodin ( Figure 1c , lane 3) and wortmannin ( Figure 1c , lane 2), while its protein level was unchanged (a-Akt). These data suggest that HER2/neu induces ILK activity through PI-3K.
HER2/neu induces resistance to various apoptotic stimuli such as TNF-a treatment. To explore the role of ILK in HER2/neu-induced resistance to TNF-a treatment, we established two stable kinase-deficient mutant ILK (ILK-KD) transfectant clones of 3T3-HER2 cells, namely, 3T3-HER2-KD-1 and KD-2 (referred as KD-1 and KD-2). As expected, 3T3-HER2 cells were more resistant to TNF-a-induced apoptosis than parental NIH3T3 cells. However, the two ILK-KD clones were much more sensitive to TNF-a treatment than either NIH3T3 or 3T3-HER2 cells (Figure 2a ). The role of ILK in the HER2/neu-induced survival pathway was further examined in an anoikis assay. NIH3T3, 3T3-HER2, and KD-1 and KD-2 cells were cultured in suspension conditions, and then their apoptotic profiles were analysed. Similar to TNF-a-induced apoptosis (Figure 2a ), 3T3-HER2 cells were resistant to anoikisinduced apoptosis as compared with the parental NIH3T3 cells, and ILK-KD clones were much more sensitive under the same conditions ( Figure 2b ). These results indicate that ILK is required for HER2/neuinduced survival signaling, which leads to resistance to TNF-a and anoikis. Previously, we have shown that HER2/neu antagonizes TNF-a-induced apoptosis by activating NF-kB. To determine whether ILK is involved in this mechanism, the transcriptional activity of NF-kB in these cell lines was examined by a luciferase reporter assay. TNF-a-induced transcriptional activity of NF-kB in 3T3-HER-2 cells was stronger than that in NIH3T3 cells, as expected. However, this induction was almost completely suppressed in the KD-1 and KD-2 cells ( Figure 2c ). Taken together, these results indicate that ILK activity is required for HER2/neu-induced NFkB activation, and blockage of ILK activity sensitizes cells to TNF-a and anoikis.
To determine how ILK regulates NF-kB activity, we examine the effects of ILK-KD on the molecules upstream of NF-kB. IkB binds to NF-kB and sequesters it in the cytoplasm. Upon TNF-a stimulation, the IKK complex phosphorylates I-kB, leading to its degradation and NF-kB activation. TNF-a treatment enhanced the degradation of IkB-a in NIH3T3 and 3T3-HER2 cells, To determine ILK kinase activity in NIH3T3 and 3T3-HER2 cell lines, cells were lysed with immunoprecipitation (IP) buffer (0.5% NP-40, 150 mM NaCl, 50 mM Tris (pH 8.0), 2% aprotinin, 5 mM PMSF, 100 mM NaF, 2 mM Na 3 VO 4 , and 1 mM EDTA). Protein (500 mg) from each sample was incubated at 41C with 1 mg of antibody or control rabbit IgG overnight and for another 2 h after the addition of protein A-agarose. The immunoprecipitates were washed with IP buffer and kinase buffer (20 mM HEPES (pH 7.4), 150 mM KCl, 5 mM MnCl 2 , 5 mM NaF, 1 mM DTT), and then resuspended in 40 ml of kinase buffer containing 5 mg of MBP as kinase substrate and 10 mCi of [g-32 P]ATP. Following 30 min incubations at 301C, the reactions were terminated with 40 ml of 2Â Laemmli SDS sample buffer. Samples were incubated for 5 min at 961C and resolved by 15% SDS-PAGE. The kinase activity of the IPs was indicated by the amount of 32 P labeling of MBP (p-MBP). (b) To determine the level of ILK protein expression in NIH3T3 (3T3) and 3T3-HER2 cell lines, protein lysates from the two cell lines were analysed by Western blotting with anti-HER2 (a-HER2), anti-ILK (a-ILK), and anti-b-actin (a-actin) antibodies. Equal amounts of protein from cell lysates were separated on 8% polyacrylamide gels and transferred to nitrocellulose filters. Each filter was blocked at room temperature for 1 h with 5% milk in PBS containing 0.05% Tween-20. They were then incubated at 41C overnight in the same solution with anti-ILK antibody (1 : 500) (Boehringer-Mannheim Corp., Indianapolis, IN, USA) and anti-Her2/neu antibody (1 : 2000). The filters were washed and incubated with horseradish peroxidase-conjugated secondary antibody for 40 min. Specific proteins were detected using an enhanced chemiluminescence system (Amersham Corp., Arlington Heights, IL, USA). (c) Tyrosine kinase inhibitor (emodin, Em) and PI-3K inhibitor (wortmannin, Wo) inhibit ILK activity. 3T3-HER-2 cells were treated with or without emodin (40 mM), or with or without wortmannin (100 nM) for 18 h. The kinase activity of immunoprecipitated ILK (upper panel) was indicated by the amount of 32 P labeling of MBP (p-MBP), as in (a). The same samples were analysed by Western blotting (lower panel) as described in (b). The molecular weight (MW) marker for PY20 blotting was labeled to indicate its position corresponding to HER2/neu Upregulation of IKKa/b by HER2/neu-ILK pathway K Makino et al but not in KD cells (Figure 3a) , suggesting that ILK-KD inhibits NF-kB activity through the stabilization of IkB-a. We then examined the effect ILK-KD had on the IKK complex in the three cell lines, since it is directly upstream of IkB. Unexpectedly, we found that IKKa (aIKKa) and IKKb (a-IKKb) protein levels were dramatically upregulated in 3T3-HER2 cells (Figure 3b (Figure 3c, lane 1) . This result, which is consistent to the pattern of IKKa and IKKb protein level in Figure 3b , suggests that HER2/neu upregulates the mRNA expression of IKKa and IKKb through ILK. It has been shown that ILK can activate Akt, a crucial mediator of survival in mammalian cells (Tan et al., 2002a) . Therefore, we next explored whether Akt was involved in the ILK-induced expression of IKKa and IKKb using a stable dominantnegative Akt (dnAkt) clone of 3T3-HER2 (3T3-HER2-dnAkt) described previously (Zhou et al., 2001 ). HER2/ neu-induced IKKa and IKKb expression were suppressed in 3T3-HER2-dnAkt cells as well as in KD cells (Figure 4a , lane 3 and 4, respectively) compared to parental 3T3-HER2 (Figure 4a, lane 2) . It should be mentioned that dnAkt inhibits Akt activity through competition for downstream substrates, and therefore does not affect the phosphorylation status of Akt ( Figure 4a , lane 2 and 3) (Zhou et al., 2001) . However, Akt phosphorylation (a-pAkt in Figure 4a Since the mRNA levels of IKKa and IKKb were enhanced by HER2/neu (Figure 3c ), we tested whether the HER2/ILK/Akt pathway may activate transcription of IKKb using the putative IKKb promoter, a 567-bp 2) were determined by Western blotting using anti-V5 tag antibody (Invitrogen, Inc., CA, USA), as shown in the inset figure. Cells were treated with TNF-a (TNF þ ) or left untreated (TNFÀ) for 48 h, and then the apoptotic cell ratio were calculated as sub-G1 population determined by flow cytometry. Data are presented as the means of three independent experiments with standard deviation. (b) ILK-KD sensitizes cells to anoikis. Cells were grown in DMEM/F12 medium containing 10% fetal bovine serum for 24 h and then plated on attached surface (ctrl) or poly-HEMA-coated plates (10 mg/ml) with 1% serum for 48 h. Cells were collected and apoptosis was analysed by a flow cytometry assay. The apoptotic cell ratios were calculated as sub-G1 population determined by flow cytometry. (c) ILK-KD inhibits the activity of NF-kB induced by TNF-a. NIH3T3, 3T3-HER2, and 3T3-HER2-KD (KD-1 and KD-2) cells were cotransfected with the pTK luciferase vector and either wild-type (WT) or mutant (MUT) NF-kB-responsive luciferase vector using the cationic liposome method in six-well plates. After 48 h of transfection, cells were incubated with ( þ ) or without (À) TNF-a (20 ng/ml) for another 12 h. Cells were lysed with 1 Â lysis buffer (Promega, Madison, WI, USA) and the luciferase activity was measured and normalized with the Dual luciferase assay kit (Promega). The WT/ MUT ratio was calculated to represent the transcriptional activity of NF-kB (Figure 4b, HER2) , and the activation was suppressed by dnAkt (Figure 4b , HER2-dnAkt) and ILK-KD (Figure 4b , HER2-ILK-KD), indicating that ILK and Akt were required for HER2/neu-mediated transcriptional activation of IKKb. Taken together, these data suggest a novel mechanism by which HER2/ neu upregulates the mRNA expression of IKKa and IKKb through ILK-induced Akt activation, resulting in NF-kB activation.
In this study, we showed that ILK mediated HER2/ neu-induced survival signaling, providing a link between and KD-2) were cultured for 18 h without serum and treated without (0) or with TNF-a (40 ng/ml) for 5 or 30 min. Protein levels of IkB-a were analysed by Western blotting using anti-IkB-a antibody (a-IkBa) (Santa Cruz Biotech., Inc., CA, USA) as described in Figure 1a . btubulin (a-tubulin), blotted by anti-b-tubulin antibody (Santa Cruz Biotech., Inc., CA, USA), was used as a protein loading control. (b) ILK-KD blocked the HER2/neu-induced IKKa and IKKb. Cell lysates prepared from NIH3T3 (3T3), 3T3-HER2, and one 3T3-HER2-KD clone (KD) were analysed by Western blotting. HER2/neu (a-HER2), ILK-KD (a-V5), and b-actin (a-actin) were blotted by the corresponding antibodies as described in Figures 1a and 2a . IKKa (aIKKa) and IKKb (a-IKKb) were blotted by anti-IKKa and antiIKKb antibody (Cell Signaling Technology, Beverly, MA, USA), respectively. Tyrosine-phosphorylated (p-Tyr) HER2/neu was detected as p-Tyr protein of 185 kDa (the size of HER2/neu) by using anti-p-Tyr antibody PY20 (Santa Cruz Biotech., Inc., CA, USA). The molecular weight (MW) marker for PY20 blotting was labeled to indicate its position corresponding to HER2/neu. (c) Northern blotting analysis of IKKa and IKKb in NIH3T3 (3T3), 3T3-HER2, and 3T3-HER2-KD cells. Total RNA was isolated from cultured cells using the Trizol (Gibco-BRL) method according to the manufacturer's instruction. RNA (10 mg) was separated by electrophoresis on a 1% agarose gel containing 0.6 M formadehyde and then transferred to blot membranes. The RNAs were UV crosslinked on the membranes, incubated in prehybridization buffer at 421C, then hybridized overnight with 32 P-labeled probes that were synthesized from cDNA expression vectors for IKKa and IKKb (provided by Dr. Jong Deng in the authors' lab) using a random primed labeling kit (Boehringer Mannheim) according to the manufacturer's protocol. The hybridized membranes were washed in 2 Â SSPE, then made visible and quantitated using a Molecular Dynamics Phosphoimager running ImageQuant software (Sunnyvale, CA, USA). The 18S ribosomal RNA (18S), stained with ethidium bromide, indicates loading control 0 -UTR of IKKb was PCR amplified using the mouse GenomeWalker Kit (Clontech, Palo Alto, CA, USA) with the designed primer UTR-1 (5 0 -AATTCCCGGGTAC-CAACACAATGGC-3 0 ) and UTR-2 (5 0 -CCGCGAATTCCCGG-GTACCAACACA-3 0 ) for primary and secondary PCR, respectively, according to the manufacturer's instruction. The secondary PCR product was cloned into pGL3-basic vector to get the reporter vector IKKb-Luc. IKKb-Luc was cotransfected with pTK luciferase vector into NIH3T3 (3T3), 3T3-HER2 (HER2), 3T3-HER2-dnAkt (HER2-dnAkt), and 3T3-HER2-KD (HER2-ILK-KD) cells. The transcriptional activity of IKKb-Luc was determined by the Dual luciferase assay as described in Figure 2c Upregulation of IKKa/b by HER2/neu-ILK pathway K Makino et al HER2/neu and integrin pathways. Previously, we have shown that HER2/neu constitutively activates NF-kB activity through the PI-3K/Akt pathway, causing resistance to TNF-a (Zhou et al., 2000) . Here, we demonstrated that ILK is required for the activation of NF-kB by HER2/neu, and identified a novel mechanism of HER2/neu-mediated IKK activation, namely, upregulation of IKKa and IKKb through ILK and Akt. In conclusion, our study identifies a novel signal cascade, HER2/neu -PI-3K -ILK -Akt -IKKa/IKKb transcription, which links the HER2/neu-mediated resistance to anoikis-and TNF-a-induced apoptosis. Therefore, together with our previous publication (Zhou et al., 2000) , there are two distinct mechanisms in which Akt may regulate the HER2/neu-mediated antiapoptotic pathway.
